Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Male single-dose HPV vaccination added to female HPV vaccination in Tanzania
ISRCTN12751107Phase 4Active, not recruiting
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of qHPV vaccine in human papillomavirus infection, Cervical Cancer (CC) and Ano-genital Carcinoma (2 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Genital quadrivalent vaccine-type HPV DNA prevalence at month 36. Started Aug 2022; status: active, not recruiting.
02
Drugs
qHPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Ano-genital Carcinoma
Beyond the preview
Go deeper on ISRCTN12751107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12751107.